United States Apixaban API Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Hisun, CTX Life Sciences, Amtec Health Care, Tianyu Pharm, Element Chemilink Pvt

Apixaban API Market is expected to grow at a CAGR of 8% during the forecast period 2024-2031

DataM Intelligence has published a new research report on "Apixaban API Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/apixaban-api-market?sg

Key Players: Neuraxpharm / INKE, Amtec Health Care Pvt. Ltd, Basic Pharma Life Science Pvt Ltd, Tianyu Pharm, Element Chemilink Pvt Ltd, Teva, Mehta API Pvt Ltd, Jinan Jianfeng Chemical Co., Ltd, Hisun, CTX Life Sciences.

USA - Industry Latest News 2025:

✅ 17 Jul 2025 - Bristol Myers Squibb / Pfizer: new direct-to-patient Eliquis (apixaban) program (US) - BMS & Pfizer announced an Eliquis patient access program (Eliquis 360 Support) that will allow eligible U.S. patients to purchase Eliquis via a program starting Sept 8, 2025. This is brand-level activity that affects market dynamics (demand for API and generics).

✅ 2025 (ongoing) - FDA generic approvals & launch timing nuance - The FDA has a history of approving generic apixaban (Eliquis) applications; however, approved generics do not always launch immediately because of patent or settlement constraints. Expect continued activity on ANDAs, 180-day first-filer status and launch timing discussions in 2025.

✅ 2025 - CDMO / API facility M&A that impacts U.S. API supply chains - Several API/CDMO acquisitions in 2025 expanded global API capacity (relevance: potential apixaban API suppliers/customers may be affected by these consolidations). Notable examples: Esteve CDMO's acquisition of Regis Technologies (US expansion) and other CDMO transactions expanding US API-capable capacity.

Japan - Industry Latest News 2025:

✅ (Historical / 2012-ongoing) - Eliquis (apixaban) is approved & marketed in Japan - Eliquis (apixaban) has been on the Japanese market (MHLW approval) for stroke prevention for years; in 2025 the market continues to be dominated by branded Eliquis with local/partnered launches and no major public 2025 M&A naming "apixaban API" specifically. Regulatory status and prescriber programs remain the main drivers.

✅ 2025 - API / CDMO activity in Japan & region (supply resilience) - While no public 2025 headline M&A explicitly said "apixaban API", Japanese CDMOs and global API suppliers have continued capacity and supply partnerships that indirectly affect apixaban API availability (no single big apixaban-API deal publicly announced in 2025). (If you want, I can deep-dive company by company.)

South Korea - Industry Latest News 2025:

✅ 12 Sep 2024 → (impactful into 2025) - Samjin Pharmaceuticals launched a generic apixaban (Elxaban) in South Korea - Local launches (like Samjin's Elxaban in Sept 2024) shaped the Korean market through 2025; expect continued generic competition and price/volume effects on apixaban API demand in 2025.

Europe - Industry Latest News 2025:

✅ 30 Jun 2025 - EUROAPI sells Haverhill (UK) site to Particle Dynamics - EUROAPI (a major European API group) announced sale of its Haverhill site as part of restructuring (this and similar deals reshape European API capacity that could affect supply of high-volume APIs such as apixaban through 2025).

✅ 7 May 2025 - HAS Healthcare (Advanced Synthesis) completes acquisition of Cerbios-Pharma SA - HAS completed acquisition of Cerbios (a recognized API manufacturer). These 2025 CDMO/API M&A moves expand/reshape European API manufacturing capacity and therefore the ecosystem that supplies apixaban API.

✅ EU regulatory / product notes - Apixaban (generic authorizations exist) - The EMA lists EU authorisations for apixaban generics (for example Apixaban Accord and other generics approved earlier). European generics and authorizations continued to be relevant through 2025, with region-by-region launches depending on patents/agreements.

Growth Forecast Projected:
The Global Apixaban API Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Apixaban API Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=apixaban-api-market?sg

Key Segments:

By Product ( 99% Purity, >99% Purity)

By Application (2.5mg Tablet, 5mg Tablet)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Apixaban API producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Apixaban API revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/apixaban-api-market?sg

FAQ's
Q1: How fast is the Apixaban API Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 8% from 2024-2031

Q2: Which regions are dominating the Apixaban API Market and which are fastest-growing?

A: North America region holds the largest market share of global apixaban API market.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/apixaban-api-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?sg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.